Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ipsen's Dysport Helps Upper Limb Spasticity in Phase 3 Trial

April 14, 2014 11:04 am | News | Comments

Ipsen announced that a first set of results on Phase 3 clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity was presented on Saturday at the World Congress for NeuroRehabilitation in Istanbul. Read more...   

TOPICS:

Janssen Posts Final Data from Phase 2 COSMOS Study

April 14, 2014 10:44 am | News | Comments

Janssen announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93% of patients with the hepatitis C virus (HCV) and advanced liver fibrosis who were treated with simeprevir and Gilead's sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). Read more...

TOPICS:

Astellas European Foundation Awards 2014 Urology Grant

April 14, 2014 10:23 am | News | Comments

The Astellas European Foundation is announced the recipient of the 2014 Functional Urology and Uro-Gynecology Grant as Dr. Marianne Gamper for a project to be undertaken jointly in Austria and Switzerland to quantify marker levels to identify the potential relationship between Overactive Bladder Syndrome and Bladder Pain Syndrome/Interstitial Cystitis. Read more...

TOPICS:
Advertisement

Abbvie’s Ribavirin Promising for Hep C Patients with Liver Cirrhosis

April 14, 2014 10:13 am | News | Comments

AbbVie announced results from the Phase 3 TURQUOISE-II, which evaluated the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's regimen with ribavirin (RBV) in adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection with compensated liver cirrhosis. Read more...

TOPICS:

Brain Cell Find Points to New Therapies

April 14, 2014 9:57 am | News | Comments

Scientists have gained new understanding of the role played by a key molecule that controls how and when nerve and brain cells are formed- a process that allows the brain to develop and keeps it healthy. Read more...          

TOPICS:

Report: GSK Bribed Doctors in Poland

April 14, 2014 9:41 am | News | Comments

The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company already faces corruption probes in China and Iraq. Read more...          

TOPICS:

Cell Models Screen Novel Meds to Regulate Body Clock

April 11, 2014 1:53 pm | News | Comments

The consequences of modern life - shift work, cell phone addiction, and travel across time zones - all disturb internal clocks found in the brain where they regulate sleep and throughout the body where they regulate physiology and metabolism. Read more...

TOPICS:

Target Promising in Asthma and Cancer

April 11, 2014 1:35 pm | News | Comments

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. Read more...

Advertisement

Collaboration Advances Use of Antibody Drug Conjugates

April 11, 2014 1:23 pm | News | Comments

PolyTherics Ltd. announced an extension to its ThioBridge antibody drug conjugate (ADC) collaboration with MacroGenics Inc., a U.S. biotechnology company developing innovative medicines utilizing its next generation antibody technologies. Read more...

TOPICS:

Expression of Tumor Suppressor Linked to Breast Cancer Survival

April 11, 2014 1:18 pm | News | Comments

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014. Read more...

TOPICS:

Study Findings May Drive Parkinson’s Treatment Research

April 11, 2014 12:51 pm | News | Comments

Scientists at Johns Hopkins University and the Institute for Cell Engineering may have discovered how the most common genetic cause of Parkinson’s disease destroys brain cells and devastates many patients worldwide. Read more...  

TOPICS:

After Setback, Impax Resubmits Parkinson’s NDA

April 11, 2014 12:36 pm | News | Comments

Impax Pharmaceuticals, a division of Impax Laboratories Inc., announced today the resubmission of Impax's NDA for Rytary (IPX066) to the FDA. IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease. Read more...

TOPICS:

Inhibiting Lactate Production Halts Tumor Growth

April 11, 2014 11:00 am | News | Comments

A research team has found that targeting the enzyme responsible for the final step of glucose metabolism not only halts tumor growth in non-small-cell lung cancer, but also leads to the regression of established tumors. Read more...       

TOPICS:

Yeast Provides Genetic Clues to Drug Response

April 11, 2014 10:45 am | News | Comments

Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Read more...   

TOPICS:

AbbVie's Hep C Regimen Posts Promising Phase 3 Results

April 11, 2014 10:36 am | News | Comments

AbbVie announced that in two Phase 3 studies, adult, non-cirrhotic patients with chronic genotype 1 hepatitis C virus infection receiving the investigational regimen with ribavirin (RBV) for 12 weeks achieved sustained virologic response rates 12 weeks post-treatment of about 96%. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading